Experts say top FDA official’s claim that Covid vaccines caused kids’ deaths requires more evidence

An internal FDA CBER memo from director Vinay Prasad alleges that a review of 96 VAERS-reported deaths from 2021–2024 identified at least 10 child deaths related to COVID-19 vaccines and calls for stricter regulatory requirements (including for vaccines in pregnancy and reconsideration of co-administered shots). The memo contains no detailed data or methodology, prompting widespread skepticism from vaccine experts and internal FDA staff, and requests for independent review; the claims could create regulatory and political risk for vaccine policy and manufacturers but lack the transparency needed to drive immediate market-moving action.

Analysis

Market structure: The memo increases idiosyncratic regulatory and reputational risk for mRNA-focused names (MRNA) and vaccine franchises; expect 5–15% downside sensitivity to adverse headlines in the near term (days–weeks) as retail/media amplify. Incumbent vaccine suppliers with diversified portfolios (JNJ, PFE) will be relatively insulated; smaller pure-plays lose pricing power for pediatric/booster markets if mandates or spacing rules are tightened.

Risk assessment: Tail risks include a formal FDA label change, ACIP revocation of booster recommendations, or state-level school policy shifts — each could reduce pediatric/booster volume 20–50% for affected products over 12–24 months. Immediate risk is volatility (IV spike) over next 7–30 days; medium-term (3–6 months) depends on whether FDA publishes the underlying data or launches an independent review; long-term (>12 months) risk is legislative/regulatory reform raising trial/approval costs for seasonal vaccines.

Trade implications: Short-duration trades should monetize elevated IV: buy 1–3 month 10–20% OTM put spreads on MRNA sized to 1–2% of portfolio for event protection; consider pairing with a 12–18 month call spread sized smaller (0.5–1%) to capture overshoot reversal. Rotate 1–3% from cyclicals into defensive healthcare (XLV or JNJ) and increase cash for headline-driven entry points; use dollar-neutral pair trades (short MRNA, long XLV) to isolate vaccine litigation/regulatory risk.

Contrarian angles: Consensus may over-weight leaked memo without data — probability of decisive regulatory action within 90 days is <25%; if no formal FDA action by ACIP meeting (next 7–30 days), expect partial recovery and compressed IV. Historical precedent (myocarditis signal) shows market overreacted then reversed once rigorous analyses arrived; selectively buy 9–18 month MRNA call spreads after a 20–30% drawdown and absent confirmatory FDA findings.

Key Decisions for Investors

• Establish a tactical hedge: buy a 1–2% portfolio-weight equivalent of 1–3 month 10–20% OTM put spreads on MRNA to protect against headline-driven drops over the next 30 days; cap max premium at ~0.5% portfolio.
• Initiate a dollar-neutral pair: short 0.75–1.5% notional MRNA and long 1–2% XLV or long 1% JNJ to isolate idiosyncratic vaccine/regulatory risk while maintaining healthcare exposure.
• Opportunistic long-backstop: if MRNA falls 20–30% from current levels without a formal FDA action within 90 days, deploy 0.5–1% portfolio into 12–18 month 25–40% OTM bull call spreads (capture mean reversion, limited downside).
• Trigger-based risk management: if FDA/ACIP announces a formal investigation or label change within 30–90 days, increase hedges to 3–5% portfolio and reduce MRNA equity exposure by 50% immediately; if no action by 90 days, reduce near-term hedges by half.
• Monitor specific catalysts over next 30–90 days: release of underlying VAERS analyses, FDA public statement, ACIP meeting minutes, and any state school-vaccine policy updates — trade size decisions must be adjusted within 48 hours of these events.